# Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

> **NCT04759131** · PHASE3 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 74 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** efanesoctocog alfa (BIVV001)

## Key facts

- **NCT ID:** NCT04759131
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-19
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-01-18
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04759131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04759131, "Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04759131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*